News

ImmuPharma soars on tumour treatment results

20 May 2008 09:02:00

Shares in specialist drug discovery and development company ImmuPharma soared Tuesday morning on the announcement of successful trials of its IPP-204106 cancer treatment.

Data on ImmuPharma's anti-cancer nucleolin antagonist ('Nucant') peptide programme, IPP-204106, confirms the treatment’s ability to effectively control and stifle the growth of a large panel of human cancer cell lines.

The studies examined the effect on breast cancer, prostate cancer, melanoma, glioblastoma, leukaemia, colon cancer and pancreatic cancer cell lines.

The treatment was effective both “in vitro” - in a controlled environment outside of a living organism – and “in vivo” – on living tissue of a living organism.

In vivo studies revealed that the majority of tumours were completely eliminated and that survival time of the patient improved with additional treatment.

ImmuPharma has filed appropriate patents on the composition of matter relating to the peptides covering a large variety of Nucant structures.

The company has also successfully developed manufacturing processes that are transferable to large scale production.

ImmuPharm has initiated the regulatory studies required for the development programme of IPP-204106, and is seeking grants from the French national research agencies.

“This exciting new drug candidate has a tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic,” said Richard Warr, chairman of ImmunPharma.

All data suppied by Digital Look (15 minute delay)




Risk Warning

There is an extra risk of losing money when shares are bought in some smaller companies including 'Penny Shares'. There is a big difference between the buying price and the selling price of these shares. If they have to be sold immediately, you may get back much less than you paid for them or you may have difficulty in selling them. Past performance is not a reliable indicator of future results. The price may change quickly and it may go down as well as up. You could lose every penny put into a particular share.

The information contained above has been compiled from documented sources which are believed to be reliable but, due to their very nature, are subject to a degree of historical inaccuracy and have not been independently verified and cannot be guaranteed. The pages on this website are provided for information only. City Equities Limited will not accept responsibility for loss incurred by any person or body acting, or refraining from acting, as a result of information and/or opinions given anywhere on this website. Issued by City Equities Limited, Aldermary House, 10-15 Queen Street, London, EC4N 1TY. Registered in England. Registered No. 2742847. Registered Address: Amwell House, 19 Amwell Street, Hoddeson, Herts. EN11 8TS. City Equities Limited is Authorised and regulated by the Financial Services Authority. Registration No. 155051.